UpToDate Stage III-IV Ovarian Cancer Drugs
UpToDate is the source of cancer drugs recommendations used by most oncologists in the United States. It conforms to the NCCN guidelines, but it provides additional information about the NCCN drugs and strategies for using those drugs.
The UpToDate late-stage Ovarian cancer drug recommendations assume the patient has previously been treated with a combination of cisplatin (a platinum drug) and paclitaxel (a taxane). Patients who respond to this drug combination for more than six months are considered platinum-sensitive, and patients who respond to this drug combination for less than six months are considered platinum resistant.
Objective Response Rate (ORR) is the percentage of patients who showed at least a partial response to a drug in a clinical trial. The table summarizes the UpToDate ORRs for each recommended drug and drug combination for platinum-sensitive and platinum-resistant patients.
| TYPE | DRUG | PLATINUM-SENSITIVE ORR | PLATINUM-RESISTANT ORR |
|---|---|---|---|
| Cytotoxic Agents | Bevacizumab (Avastin) | 44% | No Data |
| Carboplatin (Paraplatin) | 31% | No Data | |
| Cisplatin (Platinol) | No Data | No Data | |
| Docetaxel (Taxotere) | No Data | 23% | |
| Doxorubicin (Adriamycin) | 28% | 20% | |
| Etoposide (VP-16) | 34% | 27% | |
| Gemcitabine (Gemzar) | 29% | 9% | |
| Niraparib (Zejula) | No Data | 8% | |
| Olaparib (Lynparza) | No Data | 13% | |
| Paclitaxel (Taxol) | 64% | 37% | |
| Pemetrexed (Alimta) | No Data | 21% | |
| Rucaparib (Rubraca) | 20% | No Data | |
| Topotecan (Hycamtin) | 29% | 19% | |
| Other Agents | Pembrolizumab (Keytruda) | No Data | 33% |
| Tamoxifen (Soltamox) | No Data | 10% | |
| Drug Combos | Carboplatin + gemcitabine | 57% | No Data |
| Cyclophosphamide + bevacizumab | 33% | No Data | |
| BRCA+ | Olaparib (Lynparza) | No Data | 72% |
Table: Drugs Listed Alphabetically Withing Each Type
Each of these ORR values is directly attributed to a clinical trial. When there is more than one clinical trial result for the same patients and drug, the highest ORR is presented in this summary.